Zyrova Contraindications

5 mg & 40 mg: Rosuvastatin is contraindicated in the following conditions: Patients with known hypersensitivity to any component of this product. Hypersensitivity reactions including rash, pruritus, urticaria, and angioedema have been reported with Rosuvastatin patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels.
Women who are pregnant or may become pregnant. Because HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, Rosuvastatin may cause fetal harm when administered to pregnant women. Additionally, there is no apparent benefit to therapy during pregnancy, and safety in pregnant women has not been established. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus and the lack of known clinical benefit with continued using during pregnancy.
Nursing mothers. Because another drug in this class passes into breastmilk, and because HMG-CoA reductase inhibitors have the potential to cause serious adverse reactions in nursing infants, women who require Rosuvastatin treatment should be advised not to nurse their infants.
10 mg & 20 mg: Hypersensitivity to rosuvastatin or any of the other components of Zyrova. Patients with active liver disease including unexplained persistent elevations of serum transaminases.
Use in Pregnancy & Lactation: Since HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, they may cause fetal harm when administered to pregnant women. Therefore, HMG-CoA reductase inhibitors are contraindicated during pregnancy and in nursing mothers. Women of childbearing potential should use appropriate contraceptive measures.